Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGINTERVENTIONAL

Early Ileostomy Closure for Rectal Cancer Patients in North America

Early Ileostomy Closure Following Restorative Proctectomy for Rectal Cancer Patients: A North American Multicenter Randomized-Controlled Trial (RCT)

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Our preliminary work demonstrates that there is buy-in from both patients and surgeons with regards to early ileostomy closure (EIC) for select rectal cancer patients undergoing restorative proctectomy (RP) and diverting loop ileostomy (DLI). The feedback from leaders in Europe further supports the need for a large scale randomized-controlled trial (RCT) on this subject in North America. Should the results of such a study be favourable, we believe it could support a change in practice that would be beneficial to patients and the health care system alike. Furthermore, our work will help identify which patients and practices are suitable for EIC. The goal of our project is to determine whether EIC in rectal cancer patients undergoing RP with a DLI is safe, feasible and beneficial in a North American population. Specifically, our primary objective is to compare the severity of complications between patients undergoing EIC versus traditional (late) closure. Our secondary objectives include assessing the difference in quality of life (QoL), early and late bowel function, and cost of care between these two groups.

Who May Be Eligible (Plain English)

Who May Qualify: - Adult (≥18 years-old) patients - Underwent restorative proctectomy by a laparoscopic, robotic, transanal total mesorectal excision, or open approach with creation of a diverting loop ileostomy for the treatment of rectal cancer - Negative anastomotic "leak test" via CT scan with rectally-administered water-soluble contrast on post-operative day 7, 8 or 9. Who Should NOT Join This Trial: - Peri-operative immunosuppression (within 6 weeks of surgery date); - Age-adjusted Charlson Comorbidity Index \>6; - Other major surgery during the index operation; - Any major complications (Clavien Dindo Grade III or greater) following restorative proctectomy; - Inability to speak or comprehend English or French and inability to give willing to sign a consent form. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Adult (≥18 years-old) patients * Underwent restorative proctectomy by a laparoscopic, robotic, transanal total mesorectal excision, or open approach with creation of a diverting loop ileostomy for the treatment of rectal cancer * Negative anastomotic "leak test" via CT scan with rectally-administered water-soluble contrast on post-operative day 7, 8 or 9. Exclusion Criteria: * Peri-operative immunosuppression (within 6 weeks of surgery date); * Age-adjusted Charlson Comorbidity Index \>6; * Other major surgery during the index operation; * Any major complications (Clavien Dindo Grade III or greater) following restorative proctectomy; * Inability to speak or comprehend English or French and inability to give informed consent.

Treatments Being Tested

PROCEDURE

Early Ileostomy Closure

Following a negative leak test (CT scan with rectally-administered water-soluble contrast on post-operative day 7, 8 or 9), patients will undergo standardized reversal of their diverting loop ileostomy (stapled side-side functional end-to end anastomosis, purse-string closure of the ileostomy wound, and no use of epidural analgesia) between post-operative days 10-14.

Locations (4)

St. Paul's Hospital, Providence Health Care
Vancouver, British Columbia, Canada
London Health Sciences Centre
London, Ontario, Canada
Jewish General Hospital
Montreal, Quebec, Canada
McGill University Health Centre
Montreal, Quebec, Canada